Cantor Fitzgerald Downgrades Salix Pharmaceuticals (SLXP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St set to open higher as jobs data dampens rate hike odds, yields fall
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
UBS Downgrades Salix Pharmaceuticals (SLXP) to Neutral
February 24, 2015 7:22 AM ESTUBS downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $155.76 yesterday.
... MoreValeant Pharma (VRX) to Acquire Salix Pharma (SLXP) in $14.5B Deal
February 22, 2015 4:29 PM ESTValeant Pharma (NYSE: VRX) and Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies.
Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of... More
Valeant Pharma (VRX) Nears Deal for Salix Pharma (SLXP) - CNBC's Faber
February 20, 2015 9:46 AM EST(Updated - February 20, 2015 9:55 AM EST)
Valeant Pharma (NYSE: VRX) is near a deal to acquire Salix Pharma (NASDAQ: SLXP), CNBC's David Faber reported Friday.
Notably, rumors of a Salix Pharm takeover have been around... More
